Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Thromb Res. 2010 Apr;125 Suppl 2:S96-102. doi: 10.1016/S0049-3848(10)70024-4.

Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma.

Author information

  • 1Division of Hematology and Oncology, UC Davis School of Medicine, Sacramento, CA 95670, USA. twun@ucdavis.edu

Abstract

The association of malignancies and venous thromboembolism (VTE) is a long held axiom in medicine. A growing number of studies have demonstrated that the risk of VTE associated with the hematological malignancies acute leukemia, lymphoma, and multiple myeloma is considerable. In fact, the incidence associated with these malignancies exceeds that for many solid tumors. Contributing factors include malignancy associated hypercoagulable factors; antineoplastic therapies such as high dose corticosteroids, L-asparaginase, and new immunomodulatory agents; central venous catheters; and hematopoietic growth factors. Primary and secondary pharmacological prophylaxis can be problematic in these patients who are often thrombocytopenic. Strategies to prevent VTE, especially upper extremity catheter-associated thrombosis need to be developed.

PMID:
20434017
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk